NCT02346253 2026-04-13
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Stanford University
Phase NA Active not recruiting
Clinical Trials
8 trialsNCT03650894 2026-04-13
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Providence Health & Services
Phase 2 Active not recruiting
NCT05095207 2026-04-13
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT05050084 2026-04-08
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Active not recruiting
NCT04513717 2026-04-03
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT06222593 2026-04-01
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
State University of New York at Buffalo
Phase 1/2 Recruiting
NCT06365788 2026-04-01
ABBICAR
Universitaire Ziekenhuizen KU Leuven
Phase 2 Recruiting